Article Text

Download PDFPDF

Inhaled corticosteroids in COPD: quantifying risks and benefits
  1. Chris Cates
  1. Correspondence to Dr Chris Cates, PHSE, SGUL, Cranmer Terrace, London SW17 0RE, UK; ccates{at}sgul.ac.uk

Statistics from Altmetric.com

It is by no means straightforward to analyse the change in the rate of chronic obstructive pulmonary disease (COPD) exacerbations in clinical trials. Exacerbation rates do not follow a normal distribution, nor do they occur at random. High exacerbation rates in a few patients can make average rates difficult to calculate and interpret. So, surely, transforming exacerbation rates into numbers needed to treat (NNT) should help. Not necessarily so—this is the message from Professor Suissa's paper.1 He points out that the simplistic transformation from annual exacerbation rates to NNT in some published papers is misleading. He then goes on to present an alternative way of calculating NNT from survival curves showing time to first exacerbation, and a model to estimate such curves even if they are not presented.

I have used the exponential model suggested by Suissa, with the data from two of the arms of the Towards a Revolution in Chronic obstructive pulmonary disease Health (TORCH) trial2 to show how this works in practice. I chose the arms in TORCH, that compared combination fluticasone/salmeterol therapy with salmeterol alone, as this seems to me to be a fair way to estimate the impact of additional inhaled corticosteroids. Figure 1 shows pairs of modelled survival curves for pneumonia (in the upper part), and for COPD exacerbation (in the lower part). The NNT …

View Full Text

Footnotes

  • Funding Dr Cates is Coordinating Editor of the Cochrane Airways Review Group, which is funded by the National Institute for Health Research (Grants RNC/025/003 & 10/4001/01). The views and opinions expressed are those of the author and do not necessarily reflect those of the NIHR, NHS or the Department of Health.

  • Competing interests None.

  • Provenance and peer review Commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles